Rationale and design of the EVOLVE Short DAPT Study to assess 3‐month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention
Sign Up to like & getrecommendations! Published in 2018 at "American Heart Journal"
DOI: 10.1016/j.ahj.2018.08.004
Abstract: Background While extended dual antiplatelet therapy (DAPT) with aspirin and a platelet (P2Y12) inhibitor after percutaneous coronary intervention (PCI) reduces the risk of stent thrombosis (ST) and myocardial infarction (MI), it also increases bleeding. Newer… read more here.
Keywords: dapt; risk; evolve short; dapt study ... See more keywords
Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study.
Sign Up to like & getrecommendations! Published in 2020 at "Circulation"
DOI: 10.1161/circulationaha.120.047729
Abstract: Using administrative claims data to ascertain clinical events may be a pragmatic way to make randomized, controlled trials cheaper and more efficient. However, little is known about the accuracy of claims data for estimating treatment… read more here.
Keywords: dapt study; treatment effects; claims data; study ... See more keywords